166 related articles for article (PubMed ID: 18476294)
1. US FDA feels the heat from Congressional hearings.
Loewenberg S
Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
[No Abstract] [Full Text] [Related]
2. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
3. New fee structure proposed by FDA might lead to more talk.
Waters H
Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
[No Abstract] [Full Text] [Related]
4. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
5. FDA dependence on drug industry.
Lawson GW
J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
[No Abstract] [Full Text] [Related]
6. FDA joins market.
Gershon D
Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
[No Abstract] [Full Text] [Related]
7. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
8. Letter from the Commissioner's Office at the US FDA.
Vernon JA
Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801
[No Abstract] [Full Text] [Related]
9. Two-stage drug approval would reduce the risks.
Frantz JA
Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
[No Abstract] [Full Text] [Related]
10. The marketplace can't give us the drug safety data we need.
Avorn J
MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
[No Abstract] [Full Text] [Related]
11. FDA performance goals for approving drugs and biologics.
Miller JD
JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
[No Abstract] [Full Text] [Related]
12. Does neurology need a faster FDA?
Burton A
Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510
[No Abstract] [Full Text] [Related]
13. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
14. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
[TBL] [Abstract][Full Text] [Related]
15. Playing "kick the FDA"--risk-free to players but hazardous to public health.
Wood AJ
N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
[No Abstract] [Full Text] [Related]
16. Market watch: Upcoming catalysts in Q1 2015.
Uribe A
Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
[No Abstract] [Full Text] [Related]
17. User fees for faster drug reviews. Are they helping or hurting the public health?
Thompson L
FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
[No Abstract] [Full Text] [Related]
18. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
19. Where do our priorities lie?
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):353. PubMed ID: 17607292
[No Abstract] [Full Text] [Related]
20. When EMA and FDA decisions conflict: differences in patients or in regulation?
Wolfe SM
BMJ; 2013 Aug; 347():f5140. PubMed ID: 23970394
[No Abstract] [Full Text] [Related]
[Next] [New Search]
